植入式心脏监测在隐源性卒中二级预防中的应用
本研究评估植入式心脏监测(ICM)对隐源性缺血性卒中或TIA后卒中复发预防的影响。在8年期间连续纳入患者,比较常规心脏监测(前5年,门诊反复24小时Holter)与ICM持续监测(后3年)的结局。结果显示ICM组阵发性房颤检出率更高(21.1% vs 7.5%),抗凝启动率更高(18.7% vs 6.4%),卒中复发风险更低(4.1% vs 11.8%),多变量分析中ICM独立与PAF检出增加(HR=1.94)和卒中复发风险降低(HR=0.32)相关。
要点
- ICM提高隐源性卒中/TIA后阵发性房颤检出率(21.1% vs 7.5%)。
- ICM独立与PAF检出增加相关(HR=1.94,95%CI 1.16-3.24)。
- ICM独立与卒中复发风险降低相关(HR=0.32,95%CI 0.11-0.90)。
核心结论
- ICM独立与隐源性缺血性卒中或TIA后PAF检出率增加和抗凝启动率增加相关。
- ICM独立与卒中复发风险降低相关。
研究设计与样本
- 回顾性队列研究,连续纳入8年期间在综合卒中中心住院的隐源性缺血性卒中或TIA患者。
- 比较常规心脏监测组(前5年,门诊反复24小时Holter监测,373例)与ICM持续监测组(后3年,123例)。
- 采用多变量回归模型调整潜在混杂因素评估结局关联。
主要发现
- ICM组PAF检出率21.1%,常规监测组7.5%(p < 0.001)。
- ICM组抗凝启动率18.7%,常规监测组6.4%(p < 0.001)。
- ICM组卒中复发率4.1%,常规监测组11.8%(p = 0.013)。
- 多变量分析中ICM与PAF检出增加独立相关(HR=1.94,95%CI 1.16-3.24)。
- 多变量分析中ICM与卒中复发风险降低独立相关(HR=0.32,95%CI 0.11-0.90)。
临床怎么用
- 对隐源性缺血性卒中或TIA患者,可考虑植入式心脏监测以提高阵发性房颤检出并指导抗凝决策。
- ICM监测可能有助于降低卒中复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study, we sought to evaluate the impact of implantable cardiac monitoring (ICM) in the prevention of stroke recurrence after a cryptogenic ischemic stroke or transient ischemic attack (TIA). METHODS: We evaluated consecutive patients with cryptogenic ischemic stroke or TIA admitted in a comprehensive stroke center during an 8-year period. We compared the baseline characteristics and outcomes between patients receiving conventional cardiac monitoring with repeated 24-hour Holter-monitoring during the first 5 years in the outpatient setting and those receiving continuous cardiac monitoring with ICM during the last 3 years. Associations on the outcomes of interest were further assessed in multivariable regression models adjusting for potential confounders. RESULTS: We identified a total of 373 patients receiving conventional cardiac monitoring and 123 patients receiving ICM. Paroxysmal atrial fibrillation (PAF) detection was higher in the ICM cohort compared to the conventional cardiac monitoring cohort (21.1% vs 7.5%, p < 0.001). ICM was independently associated with an increased likelihood of PAF detection during follow-up (hazard ratio [HR] = 1.94, 95% confidence interval [CI] = 1.16-3.24) in multivariable analyses. Patients receiving ICM were also found to have significantly higher rates of anticoagulation initiation (18.7% vs 6.4%, p < 0.001) and lower risk of stroke recurrence (4.1% vs 11.8%, p = 0.013). ICM was independently associated with a lower risk of stroke recurrence during follow-up (HR = 0.32, 95% CI = 0.11-0.90) in multivariable analyses. INTERPRETATION: ICM appears to be independently associated with a higher likelihood of PAF detection and anticoagulation initiation after a cryptogenic ischemic stroke or TIA. ICM was also independently related to lower risk of stroke recurrence in our cryptogenic stroke / TIA cohort. ANN NEUROL 2020;88:946-955.
引用
- Triantafyllou S, Katsanos AH, Dilaveris P, et al. Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke. Ann Neurol. 2020. PMID: 32827232. doi:10.1002/ana.25886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。